SCGB1D4 Activators
SCGB1D4 employ various mechanisms to enhance the protein's activity through modulation of intracellular signaling pathways. Forskolin, a known direct stimulator of adenylyl cyclase, increases cyclic AMP levels within the cell, leading to the activation of protein kinase A (PKA). This enzyme is central to the phosphorylation of many proteins, including those associated with the function of SCGB1D4. Similarly, epinephrine and isoproterenol, both catecholamines, engage adrenergic receptors that result in elevated cAMP production and subsequent PKA activation, paving the way for SCGB1D4 activation. Anisomycin, although primarily a protein synthesis inhibitor, also activates stress-activated protein kinases, which can modify transcription factors or other proteins that regulate SCGB1D4's activity.
Chemical analogs of cAMP, such as Chlorophenylthio-cAMP and Dibutyryl-cAMP, permeate cellular membranes and directly activate PKA, which then targets proteins in the SCGB1D4 pathway. IBMX and Rolipram, both phosphodiesterase inhibitors, prevent the degradation of cAMP, thus sustaining PKA activation and the phosphorylation processes crucial for SCGB1D4 activity. Prostaglandin E2 (PGE2) engages with its specific G protein-coupled receptors, leading to a rise in cAMP and activation of PKA, which might affect SCGB1D4. In the context of specific PKA activators, Sp-5,6-DCl-cBIMPS acts as a potent stimulant for this kinase, influencing the phosphorylation status of proteins associated with SCGB1D4. Terbutaline, as a beta2-adrenergic agonist, also triggers the adenylyl cyclase-cAMP-PKA cascade, potentially influencing SCGB1D4 activity. Lastly, Zaprinast inhibits phosphodiesterase 5, thus raising not only cAMP but also cGMP levels, which can activate protein kinase G (PKG). PKG and PKA can share downstream targets, which may include proteins that interact with or regulate SCGB1D4.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine binds to and activates adrenergic receptors on the cell surface, which can lead to an increase in intracellular cAMP levels through G protein-coupled receptor signaling. This signaling cascade can activate PKA, which may then phosphorylate and activate proteins within the same pathway as SCGB1D4, leading to its functional activation. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine that activates beta-adrenergic receptors, leading to increased cAMP production via activation of adenylyl cyclase. The subsequent rise in cAMP activates PKA, which could phosphorylate SCGB1D4 or proteins that regulate SCGB1D4 activity, leading to its functional activation. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) interacts with its G protein-coupled receptors (EP receptors), which can result in increased intracellular cAMP levels. Through the activation of PKA, downstream proteins in the SCGB1D4 pathway could be phosphorylated, resulting in the activation of SCGB1D4. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
3-Isobutyl-1-methylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, leading to increased levels of cAMP by preventing its degradation. Higher cAMP levels result in enhanced PKA activity, which may activate SCGB1D4 by phosphorylating proteins in the associated signaling pathway. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that can also activate stress-activated protein kinases (SAPKs) like JNK. Activation of these kinases could lead to the phosphorylation of transcription factors or other proteins that regulate the activity of SCGB1D4, thereby leading to its activation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Dibutyryl-cAMP is another cell-permeable cAMP analog that activates PKA. This activation can lead to phosphorylation of proteins that are part of the SCGB1D4 signaling pathway, resulting in functional activation of SCGB1D4. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), which leads to an increase in cAMP levels and thereby activates PKA. Activation of PKA could influence the phosphorylation status of proteins in the pathway of SCGB1D4, leading to its activation. | ||||||
Terbutaline Hemisulfate | 23031-32-5 | sc-204911 sc-204911A | 1 g 5 g | $92.00 $378.00 | 2 | |
Terbutaline is a beta2-adrenergic agonist that leads to the activation of adenylyl cyclase and an increase in cAMP levels. The rise in cAMP activates PKA, which may phosphorylate and activate proteins that directly activate SCGB1D4. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast is an inhibitor of phosphodiesterase 5 (PDE5), leading to increased cAMP and cGMP levels. Elevated cGMP can activate protein kinase G (PKG), which may phosphoryIt appears that you have provided a list of compounds with their CAS numbers and descriptions of how they might activate the protein SCGB1D4 via the cAMP/PKA signaling pathway or related mechanisms. However, the last entry for Zaprinast was cut off. I'll complete the description for you: | ||||||